NCT03798639View on ClinicalTrials.gov

Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

December 2, 2022

Study Completion Date

December 2, 2022

Conditions
Merkel Cell CarcinomaPathologic Stage IIIA Merkel Cell Carcinoma AJCC v8Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
Interventions
BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

RADIATION

Radiation Therapy

Receive radiation therapy

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Claire Verschraegen

OTHER

NCT03798639 - Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | Biotech Hunter | Biotech Hunter